Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity

ABSTRACT: Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity

PROVIDER: PRJNA506413 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (DNA methylation data set)

Project description:We show that Glioma initiating cells (GICs) can, through MES transition, enter a reactive-astrocyte-like cell state which is connected to increased therapy resistance

2020-11-30 | GSE122808 | GEO

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (Affymetrix HTA 2.0 data set)

Project description:We show that Glioma initiating cells (GICs) can, through MES transition, enter a reactive-astrocyte-like cell state which is connected to increased therapy resistance

2020-11-30 | GSE122807 | GEO

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (DNA methylation data set)

Project description:Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (DNA methylation data set)

| PRJNA506417 | ENA

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (Affymetrix HTA 2.0 data set)

Project description:Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity (Affymetrix HTA 2.0 data set)

| PRJNA506416 | ENA

Mesenchymal transition and acquired therapy resistance of glioblastoma cells is connected to astrocyte reactivity

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-11-30 | GSE122809 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity

Project description:This SuperSeries is composed of the SubSeries listed below. Disease, injury, and aging induce pathological reactive astrocyte states that contribute to neurodegeneration. Modulating reactive astrocytes therefore represents an attractive therapeutic strategy. Here, we describe the development of an astrocyte phenotypic screening platform for identifying chemical modulators of astrocyte reactivity. Leveraging this platform for chemical screening, we identify HDAC3 inhibitors as effective suppressors of pathological astrocyte reactivity. We demonstrate that HDAC3 inhibition reduces molecular and functional characteristics of reactive astrocytes in vitro. Transcriptional and chromatin mapping studies show that HDAC3 inhibition disarms pathological astrocyte gene expression and function while promoting the expression of genes associated with beneficial astrocytes. Administration of RGFP966, a small molecule HDAC3 inhibitor, blocks reactive astrocyte formation and promotes neuroprotection in vivo in mice. Collectively, these results establish a platform for discovering modulators of reactive astrocyte states, inform the mechanisms that control astrocyte reactivity, and demonstrate the therapeutic benefits of modulating astrocyte reactivity for neurodegenerative diseases.

2024-01-10 | GSE185215 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity [scRNAseq]

Project description:Disease, injury, and aging induce pathological reactive astrocyte states that contribute to neurodegeneration. Modulating reactive astrocytes therefore represents an attractive therapeutic strategy. Here, we describe the development of an astrocyte phenotypic screening platform for identifying chemical modulators of astrocyte reactivity. Leveraging this platform for chemical screening, we identify HDAC3 inhibitors as effective suppressors of pathological astrocyte reactivity. We demonstrate that HDAC3 inhibition reduces molecular and functional characteristics of reactive astrocytes in vitro. Transcriptional and chromatin mapping studies show that HDAC3 inhibition disarms pathological astrocyte gene expression and function while promoting the expression of genes associated with beneficial astrocytes. Administration of RGFP966, a small molecule HDAC3 inhibitor, blocks reactive astrocyte formation and promotes neuroprotection in vivo in mice. Collectively, these results establish a platform for discovering modulators of reactive astrocyte states, inform the mechanisms that control astrocyte reactivity, and demonstrate the therapeutic benefits of modulating astrocyte reactivity for neurodegenerative diseases.

2024-01-10 | GSE184437 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity [BulkRNAseq.ONC]

2024-01-10 | GSE230817 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity [CUT&RUN]

2024-01-10 | GSE231598 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity [ATAC-seq]

2024-01-10 | GSE185605 | GEO